The GPT-Rosalind model is designed to accelerate biological research and drug discovery.
OpenAI has launched a new artificial intelligence model designed to support research across biology, drug discovery, and translational medicine.
The new tool, called GPT-Rosalind, is named after Rosalind Franklin, a British scientist best known for her role in the discovery of the structure of DNA.
The GPT‑Rosalind life sciences model series is built for modern scientific work across published evidence, data, tools, and experiments, the company announced on Friday.
OpenAI is increasingly turning its attention to health and medical research, developing new large language models and partnering with international pharmaceutical companies.
It is a field that artificial intelligence is already transforming, helping researchers and drugmakers identify promising compounds faster, and speeding up the pipeline from research to clinical use.
Progress in the life sciences is constrained not only by the difficulty of the science but by the complexity of the research workflows themselves, OpenAI said.
“We believe that advanced AI systems can help researchers move through these workflows faster–not just by making existing work more efficient, but by helping scientists explore more possibilities, surface connections that might otherwise be missed, and arrive at better hypotheses sooner,” the company wrote.
OpenAI said the model delivers the best performance on tasks that require reasoning over molecules, proteins, genes, pathways, and disease-relevant biology.
The company stated it is also more effective at using scientific tools and databases in multi-step workflows such as literature review, sequence-to-function interpretation, experimental planning, and data analysis.
Following this first release of GPT‑Rosalind life sciences model series, OpenAI said it will continue to expand the model’s biochemical reasoning capabilities across long-horizon, tool-heavy scientific workflows.
“We view it as the beginning of a long-term commitment to building AI that can accelerate scientific discovery in areas that matter deeply to society, from human health to broader biological research,” they wrote in the announcement.
OpenAI said it is working with biotechnology and pharmaceutical companies, and research centres such as Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific to apply GPT‑Rosalind across workflows that accelerate research and discovery.
“GPT-Rosalind represents an important step in helping scientific teams use advanced AI to reason across complex biological evidence, data, and workflows,” said Stéphane Bancel, Chief Executive Officer at Moderna.
“At Moderna, we are already seeing how it can synthesise complex data and translate those insights into experimental workflows, with the potential to accelerate the pace of R&D,” he added.
A growing bet on AI-driven science
On 14 April, OpenAI announced a partnership with the Danish pharmaceutical company Novo Nordisk to “help the company bring new and better treatment options to patients faster”.
“AI is reshaping industries, and in life sciences, it can help people live better, longer lives,” said OpenAI’s CEO Sam Altman.
The pilot programmes will launch across research and development (R&D), manufacturing, and commercial operations, aiming for full integration by the end of the year.
DW News 
